Tri-Nasal Triamcinolone Acetonide Nasal Spray 200 and 400 μg qd versus Placebo and Nasacort Triamcinolone Acetonide Nasal Aerosol 440 μg qd in Patients Suffering from Seasonal Allergic Rhinitis during the Grass Season
| Autor: | M. Stepanians, J. Shilstone, Gail G. Shapiro, Dockhorn Rj, L. Fleming, M. Valentine, G. Raphael, William R. Lumry, K. Lampl, Edwin A. Bronsky, Alan A. Wanderer, Elliot Ellis, W. Berger, J. Karafilidis, P. Korenblat, N. Lavallee, S. Pollard, C. Rohr, R. Rosenthal |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Triamcinolone acetonide Adolescent medicine.medical_treatment Nasal congestion Placebo Triamcinolone Acetonide Drug Administration Schedule law.invention 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial law otorhinolaryngologic diseases Humans Medicine 030223 otorhinolaryngology Glucocorticoids Administration Intranasal Aged Aerosols rhinorrhea business.industry Rhinitis Allergic Seasonal Middle Aged respiratory system Acetonide Otorhinolaryngology Nasal spray 030220 oncology & carcinogenesis Anesthesia Female Nasal administration medicine.symptom business medicine.drug |
| Zdroj: | American Journal of Rhinology. 12:427-434 |
| ISSN: | 1539-6290 1050-6586 |
| DOI: | 10.2500/105065898780707991 |
| Popis: | Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 micrograms once daily doses of Tri-Nasal Nasal Spray, an active control (440 micrograms once daily of Nasacort Nasal aerosol), and Tri-Nasal Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 micrograms Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|